Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Humana Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77, while Humana Inc trades at $388 (market cap $44.77B). The key difference: Humana Inc pays a 0.95% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none, and Humana Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals.
| FLRN | HUM | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $30.86 | $409.42 |
52-Week Low | $30.65 | $163.67 |
Market Cap | — | $44.77B |
Enterprise Value | — | $52.12B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN trades at $30.77, showing minimal daily change of 0.03%. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though RSI suggests potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share through mid-2026. Key financial ratios including P/E, P/S, and ROE remain unavailable in current data.
Investment outlook remains cautious due to bearish technical signals and lack of current fundamental data. The consistent dividend provides income stability, but without updated financial metrics, assessing valuation and growth prospects is challenging. Primary risks include reliance on historical dividend patterns and potential market volatility amid inflationary pressures.
Humana (HUM) trades at $388.96, up 0.9% with a neutral technical signal. The stock shows strong revenue growth reaching $129.7B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent earnings beat expectations for three consecutive quarters, while analyst consensus targets $409.93. The company maintains solid cash flow generation and recently announced key leadership appointments to strengthen its Medicaid business.
Humana presents a mixed outlook with robust revenue expansion offset by margin pressures. Investment opportunity lies in Medicare Advantage growth and cost reduction initiatives, while risks include competitive pressures and regulatory changes in healthcare. Wall Street maintains cautious optimism with 39% buy ratings amid margin recovery challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
